izpis_h1_title_alt

In vitro ciliotoxicity and cytotoxicity testing of repeated chronic exposure to topical nasal formulations for safety studies
ID Tratnjek, Larisa (Author), ID Sibinovska, Nadica (Author), ID Kristan, Katja (Author), ID Erdani-Kreft, Mateja (Author)

.pdfPDF - Presentation file, Download (6,01 MB)
MD5: DD1A032F1D013D4EB417F6FCF21DCA1C
URLURL - Source URL, Visit https://www.mdpi.com/1999-4923/13/11/1750 This link opens in a new window

Abstract
Certain active drugs and excipients of nasal formulations may impair ciliary function and mucociliary clearance. The ciliary beat frequency (CBF) is a key parameter for determining mucociliary clearance rate, and in vitro assessments of CBF have proven to be accurate and reproducible. Since topical nasal formulations are applied with repeated doses, it is essential to elucidate their chronic, as opposed to acute, effect on mucociliary clearance and nasal mucosa. The aim of this study was to assess for the first time the ciliotoxicity and cytotoxicity of nasal sprays intended for chronic treatment (with repeated doses) using a previously designed set-up for CBF measurements. For 2 weeks, the 3D nasal MucilAir™ in vitro models were treated daily with undiluted or clinically relevant doses of mometasone nasal spray, placebo nasal spray, culture medium, or they were untreated. We demonstrated a dose-dependent and time-dependent (cumulative) effect of the nasal sprays on ciliary activity and cytotoxicity using CBF measurements and ultrastructural analysis, respectively. Our results indicate that repeated administration of clinically relevant doses of mometasone nasal spray is safe for in vivo use, which is in good agreement with a previous clinical study. Overall, our study suggests that such in vitro assays have great potential for topical nasal drug screening.

Language:English
Keywords:nasal drug formulations, mucociliary clearance, cytotoxicity, ciliary beat frequency, nasal in vitro model, repeated exposure, ciliotoxicity, ultrastructural analysis, drug safety
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:18 str.
Numbering:Vol. 13, iss. 11, art. 1750
PID:20.500.12556/RUL-136220 This link opens in a new window
UDC:615.2
ISSN on article:1999-4923
DOI:10.3390/pharmaceutics13111750 This link opens in a new window
COBISS.SI-ID:81714179 This link opens in a new window
Publication date in RUL:20.04.2022
Views:736
Downloads:118
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceutics
Shortened title:Pharmaceutics
Publisher:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.11.2021

Secondary language

Language:Slovenian
Keywords:formulacije zdravil za nos, mukociliarni očistek, citotoksičnost

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Lek Pharmaceuticals, d.d., Sandoz Development Center

Funder:ARRS - Slovenian Research Agency
Project number:J7-2594
Name:Uporaba amnijske membrane za inovativno multimodalno zdravljenje bakterijskega cistitisa in raka sečnega mehurja: učinek njene protimikrobne, imunomodulatorne in protirakave aktivnosti

Funder:ARRS - Slovenian Research Agency
Project number:P3-0108
Name:Diferenciacija urotelijskih celic

Funder:ARRS - Slovenian Research Agency
Project number:I0-0022
Name:Mreža raziskovalnih infrastrukturnih centrov Univerze v Ljubljani (MRIC UL)

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back